975 related articles for article (PubMed ID: 16024619)
21. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas.
Lee JY; Dong SM; Park WS; Yoo NJ; Kim CS; Jang JJ; Chi JG; Zbar B; Lubensky IA; Linehan WM; Vortmeyer AO; Zhuang Z
Cancer Res; 1998 Feb; 58(3):504-8. PubMed ID: 9458097
[TBL] [Abstract][Full Text] [Related]
22. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia mediated expression of stem cell markers in VHL-associated hemangioblastomas.
Ponnaluri VK; Vavilala DT; Prakash S; Mukherji M
Biochem Biophys Res Commun; 2013 Aug; 438(1):71-7. PubMed ID: 23872148
[TBL] [Abstract][Full Text] [Related]
24. Loss of HNF1alpha function in human renal cell carcinoma: frequent mutations in the VHL gene but not the HNF1alpha gene.
Lemm I; Lingott A; Pogge v Strandmann E; Zoidl C; Bulman MP; Hattersley AT; Schulz WA; Ebert T; Ryffel GU
Mol Carcinog; 1999 Apr; 24(4):305-14. PubMed ID: 10326868
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.
Marxsen JH; Stengel P; Doege K; Heikkinen P; Jokilehto T; Wagner T; Jelkmann W; Jaakkola P; Metzen E
Biochem J; 2004 Aug; 381(Pt 3):761-7. PubMed ID: 15104534
[TBL] [Abstract][Full Text] [Related]
26. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
27. Tissue expression and plasma levels of adrenomedullin in renal cancer patients.
Michelsen J; Thiesson H; Walter S; Ottosen PD; Skøtt O; Jensen BL
Clin Sci (Lond); 2006 Jul; 111(1):61-70. PubMed ID: 16515534
[TBL] [Abstract][Full Text] [Related]
28. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
29. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
30. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.
Currie MJ; Gunningham SP; Turner K; Han C; Scott PA; Robinson BA; Chong W; Harris AL; Fox SB
J Pathol; 2002 Dec; 198(4):502-10. PubMed ID: 12434420
[TBL] [Abstract][Full Text] [Related]
31. Pathology, genetics and cell biology of hemangioblastomas.
Wizigmann-Voos S; Plate KH
Histol Histopathol; 1996 Oct; 11(4):1049-61. PubMed ID: 8930647
[TBL] [Abstract][Full Text] [Related]
32. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha.
Sun X; Kanwar JR; Leung E; Vale M; Krissansen GW
Gene Ther; 2003 Dec; 10(25):2081-9. PubMed ID: 14595381
[TBL] [Abstract][Full Text] [Related]
33. Von hippel-lindau disease: a genetic and clinical review.
Haddad NM; Cavallerano JD; Silva PS
Semin Ophthalmol; 2013; 28(5-6):377-86. PubMed ID: 24138046
[TBL] [Abstract][Full Text] [Related]
34. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
[TBL] [Abstract][Full Text] [Related]
36. Study of angiogenic signaling pathways in hemangioblastoma.
Pierscianek D; Wolf S; Keyvani K; El Hindy N; Stein KP; Sandalcioglu IE; Sure U; Mueller O; Zhu Y
Neuropathology; 2017 Feb; 37(1):3-11. PubMed ID: 27388534
[TBL] [Abstract][Full Text] [Related]
37. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
38. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
39. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
40. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]